Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16950059rdf:typepubmed:Citationlld:pubmed
pubmed-article:16950059lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16950059lifeskim:mentionsumls-concept:C0001792lld:lifeskim
pubmed-article:16950059lifeskim:mentionsumls-concept:C0015811lld:lifeskim
pubmed-article:16950059lifeskim:mentionsumls-concept:C1179435lld:lifeskim
pubmed-article:16950059lifeskim:mentionsumls-concept:C0040302lld:lifeskim
pubmed-article:16950059lifeskim:mentionsumls-concept:C0441640lld:lifeskim
pubmed-article:16950059lifeskim:mentionsumls-concept:C1705248lld:lifeskim
pubmed-article:16950059lifeskim:mentionsumls-concept:C0439234lld:lifeskim
pubmed-article:16950059lifeskim:mentionsumls-concept:C1548799lld:lifeskim
pubmed-article:16950059lifeskim:mentionsumls-concept:C1524073lld:lifeskim
pubmed-article:16950059lifeskim:mentionsumls-concept:C0449432lld:lifeskim
pubmed-article:16950059pubmed:issue6 Suppl 2lld:pubmed
pubmed-article:16950059pubmed:dateCreated2006-9-4lld:pubmed
pubmed-article:16950059pubmed:abstractTextTotal hip arthroplasty (THA) in patients aged 40 years and younger requires decades of increased activity demands. Between 1987 and 2000, 249 primary THAs in patients 40 years of age or younger were performed with the Mallory-Head component. The average age at THA was 34.7 years (range, 20-40 years). Follow-up averaged 91 months with 125 hips having minimum 5-year follow-up and 51 THAs having a minimum of 10 years. Four stems failed the 98.2% overall survivorship. Two stems were revised for loosening for a 99.2% (95% confidence interval, 96.4%-99.8%) survivorship with aseptic loosening as the end-point at 18 years. In young patients, this tapered titanium, proximally porous plasma-sprayed femoral component provides outstanding long-term fixation and function with significant pain relief into the second decade. Overall stem survivorship is 98.2% at up to 18 years.lld:pubmed
pubmed-article:16950059pubmed:languageenglld:pubmed
pubmed-article:16950059pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16950059pubmed:citationSubsetIMlld:pubmed
pubmed-article:16950059pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16950059pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16950059pubmed:statusMEDLINElld:pubmed
pubmed-article:16950059pubmed:monthSeplld:pubmed
pubmed-article:16950059pubmed:issn0883-5403lld:pubmed
pubmed-article:16950059pubmed:authorpubmed-author:MalloryThomas...lld:pubmed
pubmed-article:16950059pubmed:authorpubmed-author:LombardiAdolp...lld:pubmed
pubmed-article:16950059pubmed:authorpubmed-author:BerendKeith...lld:pubmed
pubmed-article:16950059pubmed:authorpubmed-author:EllisonBradBlld:pubmed
pubmed-article:16950059pubmed:issnTypePrintlld:pubmed
pubmed-article:16950059pubmed:volume21lld:pubmed
pubmed-article:16950059pubmed:ownerNLMlld:pubmed
pubmed-article:16950059pubmed:authorsCompleteYlld:pubmed
pubmed-article:16950059pubmed:pagination32-7lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:meshHeadingpubmed-meshheading:16950059...lld:pubmed
pubmed-article:16950059pubmed:year2006lld:pubmed
pubmed-article:16950059pubmed:articleTitleTapered titanium porous plasma-sprayed femoral component in patients aged 40 years and younger.lld:pubmed
pubmed-article:16950059pubmed:affiliationDepartment of Orthopaedics, The Ohio State University Medical Center, Columbus, Ohio, USA.lld:pubmed
pubmed-article:16950059pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16950059lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16950059lld:pubmed